Chemical Biology and Drug Design

MAY 10, 2025

Although it is currently only used in veterinary therapy, carprofen proves to be a molecule with a versatile therapeutic potential for human pharmacotherapy. Moreover, the molecule is a target in the drug discovery process for the development of new bioactive compounds. ABSTRACT Carprofen, a nonsteroidal anti-inflammatory drug (NSAID) derived from propanoic acid, is known for its analgesic and antipyretic properties.

Small Molecule

ProRelix Research

MAY 10, 2025

HerbalClinicalTrialsintheUSAensureadherencetokey regulationsandFDAapprovalstandardswiththeessentialcompliancechecklist. With the increasing popularity of herbal products for both preventive care and therapeutic intervention, the demand for rigorous scientific validation is stronger than ever. Herbal clinical trials in […] The post Essential Compliance Checklist for Regulations on Herbal Clinical Trials in USA appeared first on ProRelix Research.

Clinical Trials

Drugs.com

MAY 10, 2025

SATURDAY, May 10, 2025 Any parent who has been jolted awake by the squeals of a toddler with an ear infection knows that relief won't be swift or sure.Kids often build resistance to the usual days-long antibiotic treatment regimen so the pai.

Treatment

Chemical Biology and Drug Design

MAY 10, 2025

ART inhibits the resistance of RCC cells to sunitinib by promoting the ubiquitination of PAX6 through upregulation of TRIM24 expression. ABSTRACT This research aims to elucidate the mechanistic role of artesunate (ART) in enhancing the sensitivity of renal cell carcinoma (RCC) to sunitinib. To establish sunitinib-resistant RCC cell lines (786-O R and Caki-1 R), cells were treated with different concentrations of sunitinib and ART.

DNA

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

New Drug Approvals

MAY 10, 2025

Crisugabalin Cas 2209104-84-5 2-[(1 S ,2 S ,3 R ,6 S ,8 S )-2-(aminomethyl)-2-tricyclo[4.2.1.0 3,8 ]nonanyl]acetic acid WeightAverage: 209.289 Monoisotopic: 209.141578856 Chemical FormulaC 12 H 19 NO 2 HSK 16149 HSK-16149 HSK16149 Q3MK7E8686 PHASE 2 Tricyclo[4.2.1.0 3,8 ]nonane-2-acetic acid, 2-(aminomethyl)-, (1 S ,2 S ,3 R ,6 S ,8 S )- (1 S ,2 S ,3 R ,6 S ,8 S )-2-(Aminomethyl)tricyclo[4.2.1.0 3,8 ]nonane-2-acetic acid (1S,2S,3R,6S,8S)-2-(Aminomethyl)tricyclo[4.2.1.03,8]nonane-2-acetic acid 2-

International

Chemical Biology and Drug Design

MAY 10, 2025

This review explores the latest advancements in dual COX-2/5-LOX inhibitors, highlighting their potential as effective anti-inflammatory agents with improved safety profiles compared to traditional NSAIDs. ABSTRACT Chronic pain and inflammation are widespread clinical issues that significantly affect patients' quality of life and are often associated with serious conditions such as arthritis, cancer, and cardiovascular disease.

Drugs